Subject: Colchicine Limit Policy 678-H 12-2022

Drug

COLCRYS  (colchicine)

GLOPERBA  (colchicine solution)

MITIGARE  (colchicine)

Policy:

FDA-APPROVED INDICATIONS
Colcrys
Gout Flares
Colcrys (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute gout flares.
    •    Prophylaxis of Gout Flares: Colcrys is indicated for prophylaxis of
         gout flares.
    •    Treatment of Gout Flares: Colcrys tablets are indicated for
         treatment of acute gout flares when taken at the first sign of a
         flare.

Familial Mediterranean Fever (FMF)
Colcrys (colchicine, USP) tablets are indicated in adults and children four years or older for treatment of familial Mediterranean fever (FMF).

Compendial Use
Behcet’s Syndrome ⁵
Pericarditis, Recurrent; Prophylaxis ^5,6   

Gloperba
Gloperba (colchicine USP) Oral Solution is indicated for prophylaxis of gout flares in adults.

Limitations of use: The safety and effectiveness of Gloperba for acute treatment of gout flares during prophylaxis has not been studied. Gloperba is not an analgesic medication and should not be used to treat pain from other causes.

Mitigare
Mitigare (colchicine) capsules are indicated for prophylaxis of gout flares in adults.

Limitations of use: The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied. Mitigare is not an analgesic medication and should not be used to treat pain from other causes.

 

INITIAL LIMIT QUANTITY
Limits should accumulate across all drugs and strengths up to highest quantity listed   depending on the order the claims are processed. Accumulation does not apply if limit   is coded for daily dose.
Drug	1 Month Limit*	3 Month Limit*
Colcrys	120 tablets / 25 days	360 tablets / 75 days
Mitigare	60 capsules / 25 days	180 capsules / 75 days
Gloperba	300 mL / 25 days	900 mL / 75 days
*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period   to allow time for refill processing.

 

Place of Service:

Outpatient

The above policy is based on the following references:

1. Colcrys [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; May 2020.
2. Gloperba [package insert]. Alpharetta, GA: Avion Pharmaceuticals, LLC; February 2021.
3. Mitigare [package insert]. Memphis, TN: Hikma Americas Inc.; June 2020.
4. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed November 4, 2022.
5. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed November 4, 2022.
6. Imazio M, Brucato A, Cemin R, et al. Colchicine for Recurrent Pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155(7):409-414.
7. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879-895.
8. Qaseem A, Harris RP, Forciea MA, et al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:58-68.

 

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

April 23, 2023